ArticleHaematologica2025

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience.

Marika Porrazzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.